TEM,PFE Stock Price and Quote

Oct 19, 8:40 AMTempus AI reports AI H&E pre-screening panel for advanced NSCLC shows >80% sensitivity across 12 biomarkers in 60,000-patient study

Peers: GH NTRA VEEV DOCS DH HCAT EVH PHR TDOC PLTR

| Held by: ARKE ARKK VTI VB ARKG VBK VXF IBB JTEK IWP

Index	-
Market Cap	12.18B
Enterprise Value	12.81B
Income	-254.43M
Sales	1.43B
Book/sh	2.47
Cash/sh	4.52
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	3800
IPO	Jun 14, 2024

P/E	-
Forward P/E	7113.80
PEG	-
P/S	8.51
P/B	27.32
P/C	14.93
P/FCF	-
EV/EBITDA	-
EV/Sales	8.94
Quick Ratio	3.16
Current Ratio	3.30
Debt/Eq	3.25
LT Debt/Eq	3.22
Option/Short	Yes / Yes

EPS (ttm)	-1.44
EPS next Y	0.01
EPS next Q	-0.08
EPS this Y	65.44%
EPS next Y	104.50%
EPS next 5Y	-
EPS past 3/5Y	10.57% 1.21%
Sales past 3/5Y	58.29% 46.57%
EPS Y/Y TTM	-21.05%
Sales Y/Y TTM	50.43%
EPS Q/Q	112.51%
Sales Q/Q	21.56%
Earnings	Nov 02 BMO
EPS/Sales Surpr.	71.99% 0.74%

Insider Own	40.03%
Insider Trans	-2.60%
Inst Own	56.21%
Inst Trans	4.62%
ROA	-12.75%
ROE	-67.44%
ROIC	-13.56%
Gross Margin	62.92%
Oper. Margin	-18.92%
Profit Margin	-17.77%
SMA20	-8.46%
SMA50	-1.49%
SMA200	18.76%
Trades

Shs Outstand	175.02M
Shs Float	108.20M
Short Float	23.22%
Short Ratio	3.67
Short Interest	25.12M
52W High	93.46 -27.77%
52W Low	40.77 65.59%
Volatility	10.31% 8.06%
ATR (14)	5.35
RSI (14)	46.02
Beta	3.58
Rel Volume	0.03
Avg Volume	6.84M
Volume	9,548

Perf Week	-1.19%
Perf Month	-12.54%
Perf Quarter	46.73%
Perf Half Y	21.62%
Perf YTD	14.33%
Perf Year	-24.23%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	2.30
Target Price	74.94
Prev Close	66.75
Price	67.51
Change %	1.14%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-21-26	Initiated	Goldman	Neutral	$75
Sep-09-26	Initiated	UBS	Neutral	$70
Sep-08-26	Initiated	Rothschild & Co Redburn	Neutral	$67
Sep-02-26	Initiated	Cantor Fitzgerald	Overweight	$80
Sep-01-26	Upgrade	Piper Sandler	Neutral → Overweight	$76
Jun-02-26	Resumed	Wolfe Research	Peer Perform
Apr-13-26	Upgrade	TD Cowen	Hold → Buy	$65
Apr-13-26	Initiated	Jefferies	Underperform	$35
Feb-19-26	Initiated	Mizuho	Outperform	$100
Feb-17-26	Initiated	Robert W. Baird	Outperform	$59
Dec-02-25	Resumed	Morgan Stanley	Overweight	$85
Oct-21-25	Downgrade	TD Cowen	Buy → Hold	$88
Oct-20-25	Initiated	Canaccord Genuity	Buy	$110
Sep-02-25	Initiated	H.C. Wainwright	Buy	$90
Apr-21-25	Initiated	BTIG Research	Buy	$60
Feb-25-25	Downgrade	JP Morgan	Overweight → Neutral	$50 → $55
Feb-12-25	Downgrade	William Blair	Outperform → Mkt Perform
Feb-05-25	Resumed	TD Cowen	Buy	$58 → $74
Dec-13-24	Initiated	Wolfe Research	Outperform	$60
Dec-09-24	Initiated	Guggenheim	Buy	$74

Show Previous Ratings

Oct-19-26 08:30AM	Tempus Presents Data Demonstrating AI-Enabled Pre-Screening Can Help Identify Patients for Biomarker Testing in NSCLC (Business Wire)
Oct-15-26 04:01PM	Tempus to Report Third Quarter 2026 Financial Results on November 2 (Business Wire) -9.01%
Oct-13-26 07:00AM	Ambry Genetics Launches Whole Genome Sequencing Tests to Improve Rare Disease Diagnosis (InvestorsHub)
06:00AM	Ambry Genetics Announces GenomeNext, a Whole Genome Sequencing Test Solution to Improve Diagnosis for Rare Diseases (Business Wire)
Oct-09-26 10:19AM	Could You Have Seen The Run In Tempus AI Stock Coming? (Trefis)
08:30AM	Loading…
Oct-07-26 08:30AM	Tempus Announces Multi-Year Collaboration with Moderna and Merck (Business Wire)
Oct-06-26 06:47AM	Healthcare-linked stocks extend gains following possible plague death (MarketWatch) -13.85%
Oct-01-26 12:11PM	AI Drug Discovery Forecasts Vary Widely as Sector Shifts to Deployment (PR Newswire) -6.59%
08:34AM	Tempus Announces 13 Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2026 (Business Wire)
Sep-28-26 08:00AM	Tempus Receives FDA Clearance for its ECG-MR AI Product Designed to Identify Undiagnosed Mitral Regurgitation (Business Wire)
Sep-21-26 09:14AM	Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursions RNA Foundation Model (Business Wire)
Sep-18-26 05:38PM	The ARK Trade Watch: Cathie Wood Cuts Crypto Exposure, Then Reverses Course On CoreWeave (Stocktwits)
Sep-17-26 03:52PM	Will 2026 Doom and Gloom Lead to Opportunity? (Zacks) +14.85%
02:34PM	Tempus AI Stock Surges as Revenue Optimism Boosts Winning Streak (Barrons.com)
Sep-14-26 02:40PM	Tempus AI CEO Eric Lefkofsky: Healthcare will likely be the biggest beneficiary of AI (CNBC TV) +5.42%
10:00AM	Loading…
10:00AM	AI Drug Discovery Market Projected to Reach $13.8 Billion by 2033 (PR Newswire)
Sep-11-26 08:30AM	Tempus Launches Effort to Build the Largest Multimodal Whole-Genome Dataset to Advance AI-Driven Healthcare Innovation (Business Wire)
Sep-09-26 04:01PM	Tempus Secures Up to $9.5 Million in ARPA-H ADVOCATE Funding to Deploy First Autonomous AI in Cardiology (Business Wire)
09:12AM	Cathie Wood Grows Robinhood Stake; Sheds More AMD, Palantir (Investor's Business Daily)
Sep-07-26 09:49PM	The Cure for Cancer is Becoming an Investable Opportunity: Analyst Sees $600 Million for Tempus AI (BeInCrypto)
Sep-04-26 08:30AM	Tempus to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference (Business Wire)
05:30AM	The Cancer Vaccine Gold Rush Has Begun. So Has the Race for Picks and Shovels. (The Wall Street Journal)
Sep-03-26 08:55AM	AI in Drug Discovery Market Projected to Reach $8.52 Billion By 2030 (PR Newswire)
Sep-02-26 09:54AM	Sirius XM upgraded, Toast downgraded: Wall Street's top analyst calls (The Fly)
Sep-01-26 09:48AM	Cathie Wood Sold $26 Million of Palantir to Buy These Two Stocks (GuruFocus.com)
09:45AM	Piper Sandler Lifts Tempus AI to Overweight at $76 (GuruFocus.com)
09:36AM	Robinhood upgraded, Uber initiated: Wall Street's top analyst calls (The Fly)
09:36AM	Tempus AI shares rise 2.7% following analyst actions (InvestorsHub)
06:54AM	What Is Cathie Wood Buying Now? Nvidia, SpaceX And Crypto Stocks Led ARKs August Trades While Cutting These Growth Stocks (Stocktwits)
Aug-25-26 11:01PM	Tongcheng Travel Holdings Ltd (STU:TEM) (Q2 2026) Earnings Call Highlights: Resilient Growth ... (GuruFocus.com)
02:23PM	Loading…
Aug-24-26 02:23PM	What Is Really Moving Tempus AI Stock Right Now? (Trefis) -8.97%
08:30AM	Tempus Receives FDA Clearance for its AI Product Intended to Detect Signs of Pulmonary Hypertension From Standard ECGs (Business Wire)
Aug-20-26 01:22PM	TEM Stock On Track For Best Week In 4 Months Following Personalis Deal Spotlight (Stocktwits) +8.82%
Aug-19-26 01:49PM	TEM, BNTX, MRVI, RGEN, NVAX Stock Rallies As Moderna-Merck Cancer Vaccine Clears Late-stage Trial (Stocktwits) +24.09%
Aug-06-26 09:15AM	CellCarta Adds Tempus to CDx Commercialization Lab Network (PR Newswire)
Aug-04-26 08:30AM	Tempus Study Published in Nature Medicine Demonstrates Best-in-Class Performance of PRISM2 Across Diagnostic and Prognostic Applications (Business Wire)
Jul-31-26 01:12PM	Beyond Mega IPOs: ICR Capital President & Chairman Don Duffy, Live from NYSE (IPO-Edge.com)
01:02AM	Tempus AI Inc (TEM) (Q2 2026) Earnings Call Highlights: Revenue Surges 22% to $382. ... (GuruFocus.com)
Jul-30-26 04:14PM	Tempus: Q2 Earnings Snapshot (Associated Press) +6.59%
04:01PM	Tempus Reports Second Quarter 2026 Results (Business Wire)
Jul-24-26 09:10AM	A Small AI Company Just Took the Stage at One of the Biggest Events in Computing, and It Points to Where Drug Discovery Is Headed (PR Newswire) -7.22%
07:30AM	Cathie Wood's Ark Bought the Dip in Tesla Stock (Barrons.com)
Jul-22-26 08:30AM	Tempus Announces National Launch of OneOme Pharmacogenomics Testing, Advancing Patient Safety and Precision Medicine (Business Wire)
Jul-21-26 08:40AM	Tempus AI is acquiring cancer-monitoring firm Personalis in a $1.5 billion stock deal (Quartz)
08:30AM	Tempus AI acquires cancer-monitoring firm Personalis for $1.5 billion (Quartz)
07:43AM	Tempus AI acquires Personalis in $1.5bn precision oncology-focused deal (Medical Device Network)
Jul-20-26 04:56PM	Tempus AI Buys Personalis in $1.7 Billion Precision Oncology Deal (GuruFocus.com) -7.74%
03:38PM	TEM, PSNL Stocks Are Falling Why Morgan Stanley Still Likes Tempus AIs Personalis Deal (Stocktwits)
11:31AM	Tempus AI Scoops Up Personalis For $1.5 Billion; But Shares Dive (Investor's Business Daily)
11:23AM	Tempus AI to acquire cancer-monitoring firm Personalis for $1.5B (Proactive)
11:11AM	TEMs Deal To Acquire PSNL Opens Door For $20B Cancer Market Opportunity Retail Awaits To See Execution (Stocktwits)
10:44AM	Tempus AI Buys Personalis for $1.5 Billion, and Both Stocks Sink (Barrons.com)
10:38AM	Tempus to buy cancer test-maker Personalis for $1.5B (MedTech Dive)
08:35AM	Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform (Business Wire)
Jul-17-26 09:42AM	Merck Reportedly Goes To Bat In Takeover Battle. Genomics Stock Flies. (Investor's Business Daily)
Jul-09-26 09:00AM	Tempus to Report Second Quarter 2026 Financial Results on July 30 (Business Wire) +7.39%
Jul-02-26 06:41PM	CareDx Acquires Naveris, Extends Leadership into High-Growth Specialty Oncology (Exec Edge)
Jul-01-26 10:46PM	TEM Stock Slips Overnight: CEO-Linked $9.6M Share Sale Puts A Cloud Over 'AI As Physician' Story (Stocktwits) +6.34%
08:00PM	5 Under-the-Radar Stocks Fueling the AI Revolution (Oilprice.com)
09:04AM	Cathie Wood Doubles Down on AI, Loads Up on Tesla, Palantir, and SpaceX (GuruFocus.com)
09:00AM	As AI Models Become Commodities, One Bio-Native AI Company Just Moved to Patent the Thing That Actually Compounds: the Data (PR Newswire)
Jun-25-26 08:30AM	Tempus Announces Research Collaboration with Angiosarcoma Awareness, Inc. to Uncover Insights on Rare Cancers (Business Wire) +5.64%
Jun-16-26 09:11AM	16 Million People, One Underserved Disease: The AI Imaging Push to Close the Congenital Heart Gap (PR Newswire)
Jun-11-26 08:30AM	Tempus Announces Multi-Center Validation of AI-Enabled ECG Model for Predicting Atrial Fibrillation Risk Published in Heart Rhythm (Business Wire)
Jun-09-26 06:00AM	Genetics in Medicine Open Study Demonstrates How Ambry Genetics' ExomeReveal RNA Testing Can Improve Diagnostic Clarity in Exome Testing (Business Wire)
Jun-05-26 04:01PM	Tempus to Present at the Goldman Sachs 47th Annual Global Healthcare Conference (Business Wire) -11.16%
Jun-03-26 08:30AM	Tempus Launches Open-Source Digital Pathology Consortium, Names Yale New Haven Health and Leading Cancer Center as Founding Members (Business Wire)
Jun-01-26 08:30AM	Tempus Announces the Upcoming Clinical Availability of Its First Whole-Genome Sequencing Assay, xH (Business Wire)
May-31-26 08:30AM	Tempus Unveils the Next-Generation of Lens, Expanding its Agentic AI Platform for Oncology Drug Development (Business Wire)
May-30-26 08:30AM	Tempus Launches the PRECISION Challenge, a National Program Opening Its Foundation Model Work to the Broader Research Community (Business Wire)
08:00AM	Tempus Introduces 'Preview': Bridging the Critical Time Gap Between Diagnostic Order and Definitive Results (Business Wire)
May-29-26 09:15AM	Tempus Announces Initial Results from its Multimodal Foundation Model Efforts for Novel and Scalable Insight Generation in Oncology (Business Wire)
08:15AM	Tempus Receives FDA Approval for Tumor Only xT CDx, Enabling Migration of its Entire DNA Solid Tumor Portfolio (Business Wire)
May-28-26 08:30AM	Tempus Expands Next Platform to Deliver Real-Time Clinical Intelligence and Close Critical Care Gaps Across Oncology (Business Wire) +8.73%
May-27-26 08:33AM	Tempus Upgrades Its Smart Physician Platform, Hub, with Next-Generation Agentic AI Architecture to Streamline Clinical Workflows (Business Wire)
May-26-26 08:30AM	Tempus Announces 37 Abstracts Accepted for Presentation at the 2026 American Society of Clinical Oncology Annual Meeting (Business Wire)
May-20-26 02:19PM	4 Heavily Shorted AI Stocks to Watch Right Now (Schaeffer's Research)
May-19-26 08:55AM	Cardiac AI Diagnostics Stack Validation Wins Across Regulatory and Commercial Fronts (PR Newswire)
May-14-26 06:15PM	Imvivas CTA313 Lupus Drug Shows Promising Remission Results (Exec Edge)
08:30AM	Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Enhance the Probability of Success Across Clinical Development Programs In Oncology and Neuroscience (Business Wire)
May-11-26 06:00AM	Ambry Genetics' CARE Program Wins 2026 MedTech Breakthrough Award for "Best Overall Health Informatics Solution" (Business Wire)
May-08-26 12:59AM	Tempus Announces Pricing of Upsized Offering of $400.0 Million of Convertible Senior Notes (Business Wire)
May-07-26 07:11AM	Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense (Business Wire) -7.53%
May-06-26 09:31AM	Why The Dip In TEM Stock Is A Buying Window (Trefis)
May-05-26 08:21PM	Tempus AI, Inc. Q1 2026 Earnings Call Summary (Moby)
04:01PM	Tempus Reports First Quarter 2026 Results (Business Wire)
Apr-29-26 08:30AM	Tempus to Host Inaugural Investor Day on May 29, 2026 (Business Wire)
Apr-28-26 08:30AM	Tempus Named to TIME's 10 Most Influential Health and Life Science Companies of 2026 (Business Wire)
Apr-23-26 08:30AM	Tempus and USC Announce Strategic Collaboration to Accelerate AI-Driven Precision Medicine (Business Wire) -7.33%
Apr-21-26 08:30AM	Tempus to Report First Quarter 2026 Financial Results on May 5 (Business Wire)
Apr-15-26 08:30AM	Tempus and Predicta Biosciences Announce Collaboration to Expand Life Sciences Access to Ultrasensitive Whole-Genome Sequencing Assay for Hematologic Malignancies and MRD Monitoring (Business Wire) +13.89%
Apr-14-26 08:30AM	Tempus Announces 31 Abstracts for Presentation at the American Association for Cancer Research Annual Meeting 2026 (Business Wire) +7.72%
Apr-13-26 09:58AM	Nike downgraded, Starbucks upgraded: Wall Street's top analyst calls (The Fly) +7.08%
08:30AM	Tempus Launches Automated "Active Follow-Up" Service to Support Guideline-Concordant Care (Business Wire)
Apr-09-26 08:30AM	Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWE (Business Wire) -7.03%
Apr-08-26 04:01PM	Tempus to Present at the 25th Annual Needham Virtual Healthcare Conference (Business Wire)
Mar-26-26 08:57AM	Cathie Wood's Ark Dumped More Meta Stock-and Loaded Up on Another AI Stock Instead (Barrons.com)
06:34AM	Daiichi Sankyo and Tempus AI collaborate on ADC clinical development (Pharmaceutical Business Review)
04:36AM	Meta Stock Dumped by Cathie Wood. Her ARK Funds Go Big On This AI Play Instead. (Barrons.com)
Mar-24-26 03:01PM	Tongcheng Travel Holdings Ltd (FRA:TEM) Q4 2025 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Schoenherr Thomas Edward	CEO, Diagnostics	Sep 25 '26	Sale	85.00	10,281	873,885	76,740	Sep 29 04:15 PM
THOMAS SCHOENHERR	Officer	Sep 25 '26	Proposed Sale	82.24	10,281	845,509		Sep 25 04:19 PM
LEFKOFSKY ERIC P	CEO and Chairman	Sep 22 '26	Sale	77.47	250,000	19,366,630	100,000	Sep 24 04:15 PM
Eric Lefkofsky	Officer	Sep 22 '26	Proposed Sale	78.03	250,000	19,507,500		Sep 22 04:50 PM
LEFKOFSKY ERIC P	CEO and Chairman	Sep 17 '26	Sale	80.57	200,000	16,113,802	809,631	Sep 18 09:15 PM
Bartolucci Ryan M	Chief Accounting Officer	Sep 17 '26	Sale	75.00	7,062	529,650	60,804	Sep 18 09:15 PM
Polovin Andrew	EVP, Chief Legal Officer	Sep 17 '26	Sale	75.00	2,951	221,325	135,189	Sep 18 09:15 PM
Fukushima Ryan	CEO, Data	Sep 16 '26	Sale	70.00	700	49,000	15,874	Sep 18 09:15 PM
Eric Lefkofsky	Officer	Sep 17 '26	Proposed Sale	69.97	200,000	13,994,000		Sep 17 05:06 PM
RYAN BARTOLUCCI	Officer	Sep 17 '26	Proposed Sale	69.97	9,311	651,491		Sep 17 04:31 PM
ANDREW POLOVIN	Officer	Sep 17 '26	Proposed Sale	69.97	2,951	206,481		Sep 17 04:28 PM
VANESSA KUBO	Officer	Sep 16 '26	Proposed Sale	68.85	700	48,195		Sep 16 04:31 PM
JENNIFER DOUDNA	Director	Sep 01 '26	Proposed Sale	63.05	676	42,622		Sep 01 04:52 PM
VANESSA KUBO	Officer	Sep 01 '26	Proposed Sale	63.05	30,846	1,944,840		Sep 01 04:42 PM
West Nadja	Director	Aug 28 '26	Sale	69.00	3,000	207,000	31,981	Sep 01 04:15 PM
LEFKOFSKY ERIC P	CEO and Chairman	Aug 25 '26	Sale	69.87	11,848	827,857	150,000	Aug 27 08:28 PM
LEFKOFSKY ERIC P	CEO and Chairman	Aug 25 '26	Sale	68.39	238,152	16,286,612	161,848	Aug 27 08:27 PM
Eric Lefkofsky	Officer	Aug 25 '26	Proposed Sale	66.17	250,000	16,542,500		Aug 25 04:57 PM
Fukushima Ryan	CEO, Data	Aug 21 '26	Sale	70.00	14,286	1,000,020	47,420	Aug 25 04:15 PM
VANESSA KUBO	Officer	Aug 21 '26	Proposed Sale	66.65	14,286	952,162		Aug 21 04:34 PM
THOMAS SCHOENHERR	Officer	Aug 21 '26	Proposed Sale	66.65	2,694	179,555		Aug 21 04:33 PM
Fukushima Ryan	CEO, Data	Aug 18 '26	Sale	49.61	41,095	2,038,723	562,463	Aug 20 09:00 PM
LEFKOFSKY ERIC P	CEO and Chairman	Aug 18 '26	Sale	49.61	132,591	6,577,840	2,098,130	Aug 20 09:00 PM
Schoenherr Thomas Edward	CEO, Diagnostics	Aug 19 '26	Sale	58.40	8,082	471,991	89,715	Aug 20 09:00 PM
Schoenherr Thomas Edward	CEO, Diagnostics	Aug 18 '26	Sale	49.61	9,232	458,000	97,797	Aug 20 09:00 PM
Rogers James William	Chief Financial Officer	Aug 19 '26	Sale	60.00	26,313	1,578,780	106,024	Aug 20 09:00 PM
Rogers James William	Chief Financial Officer	Aug 18 '26	Sale	49.61	22,529	1,117,664	132,337	Aug 20 09:00 PM
Polovin Andrew	EVP, Chief Legal Officer	Aug 18 '26	Sale	49.61	22,148	1,098,762	146,067	Aug 20 09:00 PM
Polovin Andrew	EVP, Chief Legal Officer	Aug 19 '26	Sale	56.00	7,927	443,912	138,140	Aug 20 09:00 PM
Bartolucci Ryan M	Chief Accounting Officer	Aug 18 '26	Sale	49.61	6,175	306,342	67,866	Aug 20 09:00 PM
Eric Paul Lefkofsky	Officer	Aug 18 '26	Proposed Sale	51.64	132,591	6,846,999		Aug 19 05:03 PM
Andrew Polovin	Officer	Aug 18 '26	Proposed Sale	51.64	22,148	1,143,723		Aug 19 05:02 PM
Ryan Fukushima	Officer	Aug 18 '26	Proposed Sale	51.64	41,095	2,122,146		Aug 19 05:01 PM
Ryan M. Bartolucci	Officer	Aug 18 '26	Proposed Sale	51.64	6,175	318,877		Aug 19 04:59 PM
James William Rogers	Officer	Aug 18 '26	Proposed Sale	51.64	22,529	1,163,398		Aug 19 04:58 PM
Thomas Edward Schoenherr	Officer	Aug 18 '26	Proposed Sale	51.64	9,232	476,740		Aug 19 04:56 PM
JAMES ROGERS	Officer	Aug 19 '26	Proposed Sale	49.36	26,313	1,298,810		Aug 19 04:38 PM
ANDREW POLOVIN	Officer	Aug 19 '26	Proposed Sale	49.36	7,927	391,277		Aug 19 04:32 PM
THOMAS SCHOENHERR	Officer	Aug 19 '26	Proposed Sale	49.36	8,082	398,928		Aug 19 04:31 PM
West Nadja	Director	Aug 14 '26	Sale	53.90	3,000	161,700	34,981	Aug 18 04:15 PM
NADJA WEST	Director	Aug 14 '26	Proposed Sale	54.29	6,000	325,740		Aug 14 04:42 PM
Fukushima Ryan	CEO, Data	Aug 07 '26	Sale	50.04	20,000	1,000,800	123,945	Aug 11 05:29 PM
VANESSA KUBO	Officer	Aug 07 '26	Proposed Sale	46.12	20,000	922,400		Aug 07 04:36 PM
Epstein David R	Director	Aug 03 '26	Sale	43.40	370	16,058	31,094	Aug 05 04:30 PM
Fukushima Ryan	CEO, Data	Aug 03 '26	Sale	46.19	23,818	1,100,076	143,945	Aug 05 04:30 PM
DAVID R. EPSTEIN	Director	Aug 03 '26	Proposed Sale	43.87	990	43,431		Aug 03 04:48 PM
VANESSA KUBO	Officer	Aug 03 '26	Proposed Sale	43.87	23,818	1,044,896		Aug 03 04:17 PM
LEFKOFSKY ERIC P	CEO and Chairman	Jul 28 '26	Sale	42.06	250,000	10,514,914	200,000	Jul 30 09:42 PM
Eric Lefkofsky	Officer	Jul 28 '26	Proposed Sale	42.91	250,000	10,727,500		Jul 28 04:40 PM
Fukushima Ryan	CEO, Data	Jul 08 '26	Sale	57.39	33,284	1,910,123	167,763	Jul 10 04:15 PM
VANESSA KUBO	Officer	Jul 08 '26	Proposed Sale	60.09	33,284	2,000,036		Jul 08 04:59 PM
Fukushima Ryan	CEO, Data	Jul 06 '26	Sale	60.00	10,000	600,000	201,047	Jul 08 04:15 PM
VANESSA L KUBO	Officer	Jul 06 '26	Proposed Sale	60.27	10,000	602,700		Jul 06 04:45 PM
LEFKOFSKY ERIC P	CEO and Chairman	Jun 29 '26	Sale	57.48	166,250	9,556,389	8,775,283	Jul 01 04:15 PM
Doudna Jennifer A	Director	Jun 25 '26	Sale	55.00	2,673	147,015	25,942	Jun 29 08:40 PM
Rogers James William	Chief Financial Officer	Jun 25 '26	Sale	55.00	11,529	634,095	114,866	Jun 29 08:40 PM
Eric Lefkofsky	Officer	Jun 29 '26	Proposed Sale	56.14	166,250	9,333,275		Jun 29 05:52 PM
JAMES ROGERS	Officer	Jun 25 '26	Proposed Sale	51.94	11,529	598,816		Jun 25 04:25 PM
Epstein David R	Director	Jun 01 '26	Sale	49.40	250	12,350	31,464	Jun 03 04:28 PM
LEFKOFSKY ERIC P	CEO and Chairman	May 27 '26	Sale	46.70	166,250	7,763,312	8,808,533	May 29 04:15 PM
Eric Lefkofsky	Officer	May 27 '26	Proposed Sale	46.66	166,250	7,757,225		May 27 04:45 PM
Schoenherr Thomas Edward	CEO, Diagnostics	May 19 '26	Sale	44.07	1,580	69,631	107,029	May 21 05:05 PM
Rogers James William	Chief Financial Officer	May 19 '26	Sale	44.07	10,853	478,292	126,395	May 21 05:05 PM
Polovin Andrew	EVP, Chief Legal Officer	May 19 '26	Sale	44.07	8,703	383,541	128,215	May 21 05:05 PM
LEFKOFSKY ERIC P	CEO and Chairman	May 19 '26	Sale	44.07	22,335	984,303	2,230,721	May 21 05:05 PM
Fukushima Ryan	CEO, Data	May 19 '26	Sale	44.07	13,550	597,148	603,558	May 21 05:05 PM
Bartolucci Ryan M	Chief Accounting Officer	May 19 '26	Sale	44.07	4,116	181,392	74,041	May 21 05:05 PM
Ryan M. Bartolucci	Officer	May 19 '26	Proposed Sale	43.62	4,116	179,540		May 20 05:14 PM
James William Rogers	Officer	May 19 '26	Proposed Sale	43.62	10,853	473,408		May 20 05:13 PM
Erik Phelps	Officer	May 19 '26	Proposed Sale	43.62	6,418	279,953		May 20 05:11 PM
Thomas Edward Schoenherr	Officer	May 19 '26	Proposed Sale	43.62	1,580	68,920		May 20 05:09 PM
Andrew Polovin	Officer	May 19 '26	Proposed Sale	43.62	8,703	379,625		May 20 05:07 PM
Eric Paul Lefkofsky	Officer	May 19 '26	Proposed Sale	43.62	22,335	974,253		May 20 05:05 PM
Ryan Fukushima	Officer	May 19 '26	Proposed Sale	43.62	13,550	591,051		May 20 05:04 PM
LEFKOFSKY ERIC P	CEO and Chairman	Apr 28 '26	Sale	51.13	166,250	8,500,623	8,841,783	Apr 30 04:30 PM
Eric Lefkofsky	Officer	Apr 28 '26	Proposed Sale	52.68	166,250	8,758,050		Apr 28 04:41 PM
JENNIFER DOUDNA	Director	Apr 15 '26	Proposed Sale	49.53	3,348	165,826		Apr 15 04:39 PM
LEFKOFSKY ERIC P	CEO and Chairman	Mar 26 '26	Sale	46.38	166,250	7,711,150	8,875,033	Mar 27 09:46 PM
Eric Lefkofsky	Officer	Mar 26 '26	Proposed Sale	46.76	166,250	7,773,850		Mar 26 04:27 PM
Epstein David R	Director	Mar 02 '26	Sale	50.69	250	12,672	25,801	Mar 04 04:30 PM
Rogers James William	Chief Financial Officer	Mar 02 '26	Sale	50.69	11,414	578,576	127,248	Mar 04 04:30 PM
JAMES ROGERS	Officer	Mar 02 '26	Proposed Sale	53.25	13,583	723,295		Mar 02 04:40 PM
DAVID R. EPSTEIN	Director	Mar 02 '26	Proposed Sale	53.25	870	46,328		Mar 02 04:38 PM
LEFKOFSKY ERIC P	CEO and Chairman	Feb 19 '26	Sale	58.87	166,250	9,787,605	8,908,283	Feb 20 09:45 PM
LEFKOFSKY ERIC P	CEO and Chairman	Feb 19 '26	Sale	59.05	13,587	802,312	1,989,626	Feb 20 09:45 PM
Phelps Erik	EVP, Chief Admin. Officer	Feb 19 '26	Sale	59.43	9,464	562,472	79,816	Feb 20 06:45 PM
Bartolucci Ryan M	Chief Accounting Officer	Feb 19 '26	Sale	59.05	2,902	171,363	41,159	Feb 20 06:45 PM
Polovin Andrew	EVP, Chief Legal Officer	Feb 20 '26	Sale	60.31	10,949	660,292	126,918	Feb 20 06:45 PM
Polovin Andrew	EVP, Chief Legal Officer	Feb 19 '26	Sale	59.05	8,143	480,844	99,447	Feb 20 06:45 PM
Fukushima Ryan	Chief Executive Officer, Data	Feb 19 '26	Sale	59.05	9,592	566,408	694,354	Feb 20 06:45 PM
Rogers James William	Chief Financial Officer	Feb 19 '26	Sale	59.05	10,084	595,460	101,166	Feb 20 06:45 PM
ERIK PHELPS	Officer	Feb 20 '26	Proposed Sale	59.96	3,823	229,227		Feb 20 04:28 PM
ANDREW POLOVIN	Officer	Feb 20 '26	Proposed Sale	59.96	10,949	656,502		Feb 20 04:25 PM
Ryan M. Bartolucci	Officer	Feb 19 '26	Proposed Sale	56.16	2,902	162,976		Feb 19 09:24 PM
Andrew Polovin	Officer	Feb 19 '26	Proposed Sale	56.16	8,143	457,311		Feb 19 09:22 PM
Eric Paul Lefkofsky	Officer	Feb 19 '26	Proposed Sale	56.16	13,587	763,046		Feb 19 09:20 PM
Ryan Fukushima	Officer	Feb 19 '26	Proposed Sale	56.16	9,592	538,687		Feb 19 09:17 PM
Erik Phelps	Officer	Feb 19 '26	Proposed Sale	56.16	5,650	317,304		Feb 19 09:15 PM
James William Rogers	Officer	Feb 19 '26	Proposed Sale	56.16	10,084	566,317		Feb 19 09:13 PM
ERIK PHELPS	Officer	Feb 19 '26	Proposed Sale	56.16	3,814	214,194		Feb 19 04:43 PM

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Co-FounderMr. Eric P. Lefkofsky J.D.

Chief Financial OfficerMr. James Rogers

Executive VP and Chief Administrative & Legal OfficerMr. Erik Phelps

Chief Legal OfficerMr. Andrew Polovin

Chief Executive Officer of Data & AppsMr. Ryan Fukushima

Peers: GSK AZN BMY MRK SNY NVS ABBV JNJ AMGN LLY

| Held by: VTI VOO IVV SPY VTV XLV HDV HDV VYM DVY

Index	S&P 500
Market Cap	170.60B
Enterprise Value	222.40B
Income	4.33B
Sales	63.70B
Book/sh	14.95
Cash/sh	2.05
Dividend Est.	1.72 (5.76%)
Dividend TTM	1.72 (5.75%)
Dividend Ex-Date	Nov 06, 2026
Dividend Gr. 3/5Y	2.23% 2.37%
Payout	126.85%
Employees	75000
IPO	Jan 17, 1944

P/E	39.63
Forward P/E	10.33
PEG	-
P/S	2.68
P/B	2.00
P/C	14.58
P/FCF	15.53
EV/EBITDA	9.46
EV/Sales	3.49
Quick Ratio	0.96
Current Ratio	1.27
Debt/Eq	0.74
LT Debt/Eq	0.71
Option/Short	Yes / Yes

EPS (ttm)	0.76
EPS next Y	2.90
EPS next Q	0.73
EPS this Y	-8.07%
EPS next Y	-2.08%
EPS next 5Y	-8.26%
EPS past 3/5Y	-37.19% -3.57%
Sales past 3/5Y	-14.56% 8.48%
EPS Y/Y TTM	-59.71%
Sales Y/Y TTM	-0.21%
EPS Q/Q	-108.60%
Sales Q/Q	2.60%
Earnings	Nov 03 BMO
EPS/Sales Surpr.	12.87% 4.41%

Insider Own	0.09%
Insider Trans	2.18%
Inst Own	69.71%
Inst Trans	-0.48%
ROA	2.13%
ROE	4.99%
ROIC	2.97%
Gross Margin	64.83%
Oper. Margin	26.57%
Profit Margin	6.80%
SMA20	4.58%
SMA50	6.33%
SMA200	12.38%
Trades

Shs Outstand	5.70B
Shs Float	5.69B
Short Float	2.64%
Short Ratio	4.34
Short Interest	150.22M
52W High	30.25 -1.05%
52W Low	23.62 26.72%
Volatility	1.94% 1.89%
ATR (14)	0.54
RSI (14)	69.18
Beta	0.27
Rel Volume	0.03
Avg Volume	34.62M
Volume	44,191

Perf Week	2.47%
Perf Month	7.17%
Perf Quarter	19.68%
Perf Half Y	11.69%
Perf YTD	20.21%
Perf Year	20.45%
Perf 3Y	-2.34%
Perf 5Y	-30.16%
Perf 10Y	-1.85%
Recom	2.66
Target Price	28.99
Prev Close	30.11
Price	29.93
Change %	-0.59%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-06-26	Downgrade	HSBC Securities	Buy → Hold	$28
Jun-10-26	Upgrade	RBC Capital Mkts	Underperform → Sector Perform	$25
Mar-02-26	Upgrade	Argus	Hold → Buy	$35
Feb-25-26	Initiated	RBC Capital Mkts	Underperform	$25
Feb-20-26	Initiated	Barclays	Underweight	$25
Feb-12-26	Downgrade	Daiwa Securities	Outperform → Neutral	$27
Jan-07-26	Resumed	UBS	Neutral	$25
Dec-02-25	Resumed	Citigroup	Neutral	$26
Nov-13-25	Initiated	Scotiabank	Sector Outperform	$30
Apr-22-25	Initiated	Cantor Fitzgerald	Neutral	$24
Dec-10-24	Resumed	BofA Securities	Neutral	$29
Nov-15-24	Initiated	Wolfe Research	Underperform	$25
Oct-25-24	Resumed	Citigroup	Neutral	$30
Oct-17-24	Initiated	Bernstein	Mkt Perform	$32
Aug-07-24	Upgrade	Daiwa Securities	Neutral → Outperform
Mar-22-24	Downgrade	Argus	Buy → Hold
Feb-23-24	Initiated	Guggenheim	Buy	$36
Jan-04-24	Downgrade	TD Cowen	Outperform → Market Perform	$32
Oct-20-23	Resumed	UBS	Neutral	$36 → $34
Oct-16-23	Upgrade	Jefferies	Hold → Buy	$38 → $39

Show Previous Ratings

Oct-20-26 06:03PM	Stephen K. Brannan, MD, and John D. Young Appointed to Slate Medicines Board of Directors (Exec Edge)
02:53PM	Wall Street rises with investors rotating into healthcare and value stocks (Reuters)
Oct-17-26 12:15PM	Pfizer or Kraft Heinz: Only One Gets My Dividend Dollars for the Next 10 Years (TIKR)
Oct-16-26 10:57PM	What Was Eli Lilly Telling You Before Its Stock Ran? (Trefis)
08:53PM	When Amgen's Forecast And Chart Say The Same Thing, Pay Attention (Trefis)
08:37PM	Loading…
08:37PM	Gileads HIV Prevention Business Just Topped $1 Billion A Quarter. What Comes Next? (Trefis)
08:13PM	Is Amgen Stock Increasing Your Market Risk? (Trefis)
10:44AM	What Is The Case For Waiting On Moderna Stock? (Trefis)
Oct-15-26 03:59PM	Better Dividend Stock: Pfizer vs. GSK (TIKR)
03:46PM	How Has Merck's Story Changed? (Trefis)
09:09AM	Where Could Johnson & Johnson's Next Growth Come From? (Trefis)
05:30AM	Big Pharma Is Pouring Billions Into a New Class of 'Protein Degrader' Drugs (The Wall Street Journal)
Oct-14-26 11:47PM	Why Did GME, BMBL, PFE Stocks Hit 52-Week Highs Today? (Stocktwits)
09:47PM	How Much Downside Is Left In Liquidia Stock? (Trefis)
05:45PM	What Could Send Regeneron Stock Higher? (Trefis)
03:34PM	Loading…
03:34PM	Better High-Yield Dividend Stock: Pfizer vs. General Mills (TIKR)
03:25PM	Better High-Yield Dividend Stock: Pfizer vs. British American Tobacco (TIKR)
03:12PM	Better High-Yield Dividend Stock: Pfizer vs. UPS (TIKR)
03:01PM	Better High-Yield Dividend Stock: Pfizer vs. Healthpeak (TIKR)
02:40PM	Better High-Yield Dividend Stock: Pfizer vs. Edison International (TIKR)
02:34PM	Better High-Yield Dividend Stock: Pfizer vs. Clorox (TIKR)
09:31AM	J&J earnings set negative tone; Shkreli vs. the FTC (BioPharma Dive)
08:18AM	The Open Question Under Johnson & Johnson Stock's Price (Trefis)
06:45AM	Pfizer Showcases Clinical Advancements Across Infectious Diseases at IDWeek 2026 (Business Wire)
06:39AM	Pfizer partners with Enodia Therapeutics in $500m drug deal (Pharmaceutical Business Review)
Oct-13-26 07:48PM	Is Amgen Stock Worth More Than Its Competitors? (Trefis)
04:20PM	Pfizer or Enbridge: Only One Gets My Dividend Dollars for the Next 10 Years (TIKR)
03:59PM	What Does Bristol-Myers Squibb Offer That Pfizer Does Not? (Trefis)
03:24PM	What Is Eli Lilly Stock's Biggest Opportunity? (Trefis)
03:00AM	Ozempic face powers revival of a fading British giant (The Telegraph)
05:01PM	Loading…
Oct-12-26 05:01PM	Where Could Moderna's Next Growth Come From? (Trefis)
10:15AM	Bristol Myers Stock Is Rising on a Double Dose of Good News (Barrons.com)
Oct-11-26 09:22PM	SLS Stock Jumps Overnight: Retail Sees Big Pharma Buyout Clues In 'M&A Negotiation Lounge' Booth At ASH (Stocktwits)
Oct-10-26 12:06PM	Four Analysts Raised Their Pfizer Targets in One Week Without an Upgrade. Heres Where the Stock Could Go By 2030 (TIKR)
Oct-09-26 08:47PM	Why Is Everyone Ignoring Gilead Stock's High Cash Yield? (Trefis)
08:09PM	BNTX, NVAX, MRNA Lead Vaccine Rally After Report Of An NIH Cancer-Vaccine Push (Stocktwits)
04:13PM	Moderna stock hits 4-year high on planned national cancer vaccine effort (Yahoo Finance)
03:39PM	Top Research Reports for JPMorgan, ASML & Chevron (Zacks)
02:12PM	Does The Move In Merck Stock Change Anything? (Trefis)
12:14PM	Moderna stock jumps on planned national cancer vaccine effort (Yahoo Finance)
11:18AM	FDA review docs spark Revolution sell-off; Zealand diabetes data underwhelm analysts (BioPharma Dive)
Oct-08-26 08:36PM	Should You Be Worried About Pfizer Stock? (Trefis)
08:19PM	What Is Going On With Regeneron Stock? (Trefis)
09:35AM	PFE, LLY, MRK Stocks In Focus: Cantor Raises Price Targets On Pharma Behemoths, But Flags Growth Concerns For Pfizer (Stocktwits)
09:04AM	Medicus Pharma targets partnerships and clinical milestones as oncology pipeline advances (Proactive)
09:03AM	What Would It Take For Amgen Stock To Move Higher? (Trefis)
07:07AM	FDA approves Pfizer's Tukysa regimen for metastatic breast cancer (Pharmaceutical Business Review)
Oct-07-26 07:14PM	Is Exelixis Stock Engineered To Make You Money? (Trefis)
12:57PM	Pfizer's TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast Cancer (Business Wire)
12:13PM	Why You Should Think About Eli Lilly Stock Differently Now (Trefis)
Oct-06-26 07:30PM	Astellas Highlights Data Advancing Cancer Care and Innovation for Patients with Hard-to-Treat Cancers at ESMO 2026 (PR Newswire)
04:48PM	Novavax, Moderna stocks fall after WHO calls plague risk 'low' (Yahoo Finance)
10:00AM	Pfizer Declares Fourth-Quarter 2026 Dividend (Business Wire)
08:44AM	Vaxcyte VAX-31 pneumococcal vaccine phase 3 trial results (Quartz)
01:38AM	Pfizers $6.49 Billion Prevnar Franchise Faces a New Challenger (TIKR)
Oct-05-26 02:37PM	PCVX Stock Hits Fresh 52-Week High On Late-Stage Win In Adult Pneumonia Vaccine Race: Jefferies Says It Hit Blue-Sky Case (Stocktwits)
02:18PM	Drug stocks show rare weakness amid fears of vaccine competition (MarketWatch)
10:43AM	Vaxcyte Soars 36% on Phase 3 Pneumococcal Vaccine Win That Sets a New Benchmark (TIKR)
10:39AM	Vaxcytes stock up after pneumococcal vaccine proves non-inferiority (Clinical Trials Arena)
10:32AM	Vaxcyte shares surge on late-stage vaccine trial success (Proactive)
10:23AM	Vaxcyte Stock Spikes 57% as Lead Vaccine Candidate Takes Aim at Pfizer and Merck (Barrons.com)
10:19AM	Has Eli Lilly Stock Peaked? (Trefis)
10:01AM	Vaxcyte Catapults After Going Toe-To-Toe With Pfizer, Merck In Vaccine Study (Investor's Business Daily)
09:52AM	Vaxcyte skyrockets on near best-case pneumococcal vaccine data (BioPharma Dive)
07:57AM	EADV26: Key late-stage readouts from the conference (Clinical Trials Arena)
Oct-02-26 11:37AM	Pfizers Eczema Drug Hit a 61% Response Rate the Day Florida Sued. Heres What It Means for the Stock (TIKR)
11:15AM	Pfizer's LITFULO Significantly Improved Facial and Total Body Repigmentation in Patients with Nonsegmental Vitiligo (Business Wire)
06:27AM	How Has Pfizer's Story Changed? (Trefis)
Oct-01-26 01:09PM	Pfizer Scores Promising Win for Experimental Eczema Drug (GuruFocus.com)
11:41AM	What Is The Options Market Telling Us About Eli Lilly Stock? (Trefis)
02:30AM	Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study (Business Wire)
Sep-30-26 03:01PM	Was The Run In JNJ Stock Hiding In Plain Sight? (Trefis)
12:19PM	Invivyds Covid-directed mAb hits Phase III safety goals (Clinical Trials Arena)
11:34AM	PFE vs. BMY: Each Faces a $22 Billion+ Patent Cliff. One Dividend Looks Much Safer (TIKR)
11:29AM	Are You Overpaying For Pfizer Stock Versus Its Rivals? (Trefis)
10:43AM	What Is Merck Stock's Biggest Opportunity? (Trefis)
Sep-29-26 04:59PM	AstraZeneca Digs $2 Billion Out Of Its Coffers For Summit Deal, Taking On Bristol, Pfizer, Merck (Investor's Business Daily)
02:43PM	Is Eli Lilly Stock a Good Fit For Your Portfolio Risk? (Trefis)
12:23PM	Management Raised the Bar For Eli Lilly Stock; Does The Chart Agree? (Trefis)
Sep-28-26 04:33PM	$85 Billion And Counting: JNJ Stock's Steady Cash-Return Habit (Trefis)
02:08PM	What Are Merck Stock Investors Overlooking? (Trefis)
10:06AM	BioNTech to Close Manufacturing Sites in Germany and Singapore After Sale Process Ends (InvestorsHub)
08:50AM	What Bavarian Nordics next CEO is up against (Pharma Voice)
06:45AM	Pfizer Advances Today's Cancer Care and Tomorrow's Potential Breakthroughs at ESMO (Business Wire)
Sep-27-26 08:46AM	Innovation Is Driving a New Bull Market in Biotech. 16 Ways to Play It, From Our Roundtable Experts. (Barrons.com)
Sep-25-26 01:13PM	Is LLY Stock Cheaper Than It Looks? (Trefis)
01:03PM	Pfizer Stock Paid Out $49B: So Why Did Investors Lose Money? (Trefis)
11:39AM	Innovation Is Driving a New Bull Market in Biotech. 16 Ways to Play It, From Our Roundtable Experts. (Barrons.com)
Sep-24-26 03:03PM	Can Eli Lilly Stock Catch Up To Rivals It Outgrows? (Trefis)
Sep-23-26 01:18PM	What Is AbbVie No Longer Telling You? (Trefis)
12:53PM	Moderna CEO's Surprising Comment Gives Clues About Where Drugmaker Is Going Next (Barrons.com)
12:37PM	What Is The Best Case For Pfizer Stock? (Trefis)
10:39AM	Pfizers International Chief Just Explained How the Turnaround Actually Works. Heres Where the Stock Could Go (TIKR)
Sep-22-26 01:39PM	Was Moderna Stock's Cancer Vaccine Run Visible In Advance? (Trefis)
10:00AM	Pfizer Invites Public to View and Listen to Webcast of November 3 Conference Call with Analysts (Business Wire)
09:50AM	Could You Have Seen Merck Stock's Pipeline Run Coming? (Trefis)
09:40AM	Why Is JNJ Stock Beating Rivals That Grow Faster? (Trefis)
Sep-21-26 12:43PM	NYC Office-to-Residential Conversions Keep Gaining Steam (CRE Daily)
10:40AM	Huge News For Pfizer Stock Fans (GuruFocus.com)
10:17AM	What Would It Take For Pfizer To Cut Its Dividend? (Trefis)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BOURLA ALBERT	Chairman & CEO	Aug 12 '26	Buy	26.34	38,000	1,000,920	429,173	Aug 12 04:04 PM
DAMICO JENNIFER B.	SVP & Controller	Aug 05 '26	Sale	25.40	3,278	83,261	28,611	Aug 06 11:26 AM
BLAYLOCK RONALD E	Director	Aug 05 '26	Buy	25.46	39,231	998,821	66,938	Aug 05 04:03 PM
Buckley Mortimer J	Director	Aug 05 '26	Buy	25.52	37,632	960,369	37,632	Aug 05 04:02 PM
DAMICO JENNIFER B.	SVP & Controller	Jun 09 '26	Sale	25.70	2,000	51,400	31,397	Jun 10 07:58 PM
SAHNI PAYAL	Executive Vice President	Feb 25 '26	Option Exercise	33.82	56,888	1,923,952	82,816	Feb 27 06:35 PM
LANKLER DOUGLAS M	Executive Vice President	Feb 25 '26	Option Exercise	33.82	122,907	4,156,715	282,186	Feb 27 06:35 PM
DAMICO JENNIFER B.	SVP & Controller	Feb 25 '26	Option Exercise	33.82	17,558	593,812	29,744	Feb 27 06:35 PM
BOURLA ALBERT	Chairman & CEO	Feb 25 '26	Option Exercise	33.82	491,626	16,626,791	864,215	Feb 27 06:34 PM
Fonseca Lidia	Executive Vice President	Feb 25 '26	Option Exercise	33.82	56,888	1,923,952	101,579	Feb 27 06:34 PM
McDermott Michael	Executive Vice President	Feb 25 '26	Option Exercise	33.82	37,925	1,282,624	114,534	Feb 27 06:34 PM

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Ph.D.Dr. Albert Bourla D.V.M.

M.D.Dr. Chris Boshoff FMedSci

Executive VP & Chief Legal OfficerMr. Douglas M. Lankler

Executive VP & Chief U.S. Commercial OfficerMr. Aamir Malik

Interim CFO & Executive VPMs. Cecile Guegan

TEM

Tempus AI Inc

PFE

Pfizer Inc

Upgrade your Finviz experience